Drug-induced subacute cutaneous lupus erythematosus

Abstract

Subacute cutaneous lupus erythematosus (SCLE) is a subset of cutaneous lupus erythematosus with unique immunologic and clinical features. The first description dates back to 1985 when a series of five patients were found to have hydrochlorothiazide-induced SCLE. Since that time, at least 40 other drugs have been implicated in the induction of SCLE.

General Aspects of Adverse Cutaneous Drug Reactions

“…ANA, anti-Ro/SSA, anti-La/SSB antibodies may be found positive [ 66 ], whereas antihistone antibodies might be absent [ 65 ]. Among the cardiovascular drugs, thiazide diuretics, CCBs, and statins have been more commonly implicated to trigger SCLE [ 67 , 68 ].…”

Drug-Induced Subacute Cutaneous Lupus Erythematosus—Filling the Gap in Knowledge

“…During almost 3 decades since that publication, multiple drugs have been linked to this phenomenon, now numbering more than 100 agents, and the occurrence of a drug as a cause or as an exacerbating agent represents roughly 20% of newly diagnosed cases of SCLE. 3 There is a lack of understanding about the difference between drug-induced SCLE (DI-SCLE) and drug-induced systemic lupus erythematosus (SLE) (DI-SLE). A misunderstand-ing about the serologic profile of DI-SCLE also exists.…”

Manifestations cliniques et biologiques Diagnostic du lupus érythémateux

“…l'hydrochlorothiazide, le diltiazem, la terbinafine, les anti-TNFα, les IFNs, la griséofulvine, le paclitaxel, la ranitidine, le 5FU, les inhibiteurs de la pompe à protons [63]. À l'arrêt du produit inducteur, les signes cliniques disparaissent en quelques jours à quelques mois, nécessitant parfois l'adjonction de corticoïdes.…”